Joint Transnational Calls

EP PerMed has planned to launch at least one annual Joint Transnational Call for research proposals in the years 2024 to 2030. The funding of transnational collaborative research is thereby a joint activity to further enhance the cooperation between stakeholders across Europe and beyond to maximise the benefits of Personalised Medicine (PM) approaches and thus pooling resources and achieving investments of scale in this field.

To ensure efficient utilisation and accessibility of new and improved PM approaches, project consortia should be both multidisciplinary and intersectoral in EP PerMed calls for proposals. This includes involving academia (universities, research performing organisations both public and private not for profit), clinical settings and public health organisations, and enterprises (spin-offs, start-ups, small and medium size enterprises, biotechnology and health/pharma industries). Participatory research approaches are also encouraged involving patients, citizens, clinicians and healthcare providers.

Of note, applications submitted to EP PerMed must be in the field of Personalised Medicine

PM represents a paradigm shift from a “one size fits all” approach to an optimised strategy for the prevention, diagnosis and treatment of disease for each individual, based on their unique characteristics, including biological features (e.g. phenotype, endotype, genotype), as well as lifestyle and environmental factors. Accordingly, PM puts the patient at the very centre of healthcare, aiming for optimised health promotion, treatments and management of disease or predisposition to disease. Today, the field of PM has been advancing rapidly, and the range of technologies, methodologies and information utilised is much broader, supporting improved healthcare, diagnostics and tailormade treatments, including rehabilitation, and prevention strategies.